Novartis Glivec Patent Case: Section 3(d), Efficacy and Access
Reviewed by CA Nikhil Gupta · Last reviewed 21 June 2026
The Glivec judgment is often reduced to a conflict between patents and access to medicines. Its legal core was narrower: whether the claimed beta-crystalline form met India’s patentability requirements, including Section 3(d).
Current position
On 1 April 2013, the Supreme Court dismissed Novartis’s appeal. In applying Section 3(d), the Court examined whether the new form demonstrated enhanced therapeutic efficacy over the known substance. The judgment did not declare that all pharmaceutical improvements are unpatentable or that cost alone decides patentability.
Key facts at a glance
| Supreme Court judgment | 1 April 2013 |
|---|---|
| Provision | Section 3(d) of the Patents Act, 1970 |
| Core test | Enhanced therapeutic efficacy for the claimed new form |
| Scope caution | The ruling does not bar every incremental pharmaceutical invention |
What this means in practice
1. Read the substance
Patent strategy must link technical improvement to the statutory legal test.
2. Measure the right risk
Better stability or handling may be commercially useful without necessarily proving enhanced therapeutic efficacy.
3. Turn the lesson into a control
Public-health context matters, but legal conclusions must follow the claim, prior art and evidence.
Practical example
A modified medicine may dissolve better and store longer. Those benefits can be valuable, but a Section 3(d) analysis asks whether evidence establishes the required enhancement in therapeutic efficacy.
A four-step decision framework
1. Identify the exact entity and period
Start with the legal entity, forum, reporting period or product actually covered. In this article, the first anchor is supreme court judgment: 1 April 2013. Similar brand names or later events should not be assumed to have the same treatment.
2. Reconcile the number with its definition
The next anchor is provision: Section 3(d) of the Patents Act, 1970. Check whether a figure is a balance, flow, claim, estimate, transaction value, accounting revenue or management-reported operating metric before comparing it.
3. Read the operative status
Use the latest applicable order, filing or policy statement and note its date. Do not rely on an older headline where an appeal, implementation step, later law or winding-up event has changed the position.
4. Convert the lesson into a control
The useful output is a documented action: Read the latest operative order relating to Novartis Glivec Patent Case, not only a news report. Assign an owner, a deadline and the evidence needed to show that the control worked.
Action checklist
- Read the latest operative order relating to Novartis Glivec Patent Case, not only a news report.
- Separate allegations, interim findings, final orders, appeals and implementation status.
- Create a dated chronology with parties, forum, case number and relief.
- Map financial exposure to the specific legal outcome and enforcement stage.
- Keep public wording limited to what reliable records support.
Evidence and document checklist
- Operative court, tribunal or regulator order
- Appeal, stay or settlement record
- Contracts, board papers and contemporaneous correspondence
- Claim, security and payment documents
- Dated chronology with source links
Common mistakes and red flags
Common mistakes
- Treating an allegation as a final finding
- Quoting an old order without checking appeal status
- Extending a finding to unnamed people or entities
- Confusing approved plans with completed implementation
Red flags
- No copy of the operative order
- Different entities grouped under one brand name
- Large financial conclusion based on a press headline
- Status language such as 'convicted' or 'cleared' without the exact record
Escalation route
Seek specialist legal advice where rights, limitation periods, appeals or enforcement are involved. Use the regulator or tribunal process applicable to the precise entity and issue.
2026 Accuracy & Decision Check
Anchor the case study to the Supreme Court’s 2013 judgment, not a generic policy source
The controlling Indian case is Novartis AG v Union of India, Civil Appeal Nos. 2706–2716 of 2013 and connected matters. The Supreme Court’s judgment is the primary source for the Glivec/section 3(d) analysis. The article’s broader conclusion about balancing innovation and access is interpretation and should be kept separate from the Court’s actual holdings.
Decision / evidence controls
- Use the Supreme Court judgment for facts, procedural history and holdings.
- Distinguish section 3(d) patentability analysis from a general rule that incremental pharmaceutical inventions can never be patented.
- Avoid attributing later drug-pricing or access outcomes directly to the judgment unless independently evidenced.
- Keep policy commentary clearly labelled as analysis.
Primary-source checks
Frequently Asked Questions
Source and review trail
Use the current official instrument, portal or regulator publication before acting. This panel separates the category authority from page-specific references.
- Primary category
- Startup Finance & Cap Tables
- Official starting point
- www.startupindia.gov.in
Page source links
The prior page did not embed a page-specific external source. The category authority above is the minimum verification starting point; a specific instrument should be added when available.